Healthcare provider profile · identity verified

Ali R Moazzami, MD

Family Practice · RANCHO MIRAGE, CA · NPI 1720576168

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	652	269
Amlodipine Besylate	Amlodipine Besylate	492	195
Losartan Potassium	Losartan Potassium	320	137
Lisinopril	Lisinopril	259	106
Metformin Hcl Er	Metformin Hcl	141	64
Rosuvastatin Calcium	Rosuvastatin Calcium	136	63
Hydrochlorothiazide	Hydrochlorothiazide	130	57
Metformin Hcl	Metformin Hcl	130	54
Atenolol	Atenolol	129	49
Levothyroxine Sodium	Levothyroxine Sodium	125	43
Metoprolol Tartrate	Metoprolol Tartrate	116	49
Omeprazole	Omeprazole	109	59
Glipizide	Glipizide	104	40
Simvastatin	Simvastatin	103	41
Potassium Chloride	Potassium Chloride	97	42
Albuterol Sulfate Hfa	Albuterol Sulfate	95	51
Furosemide	Furosemide	91	38
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	85	36
Jardiance	Empagliflozin	83	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	82	31
Hydralazine Hcl	Hydralazine Hcl	80	37
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	75	36
Meloxicam	Meloxicam	73	40
Spironolactone	Spironolactone	62	23
Pantoprazole Sodium	Pantoprazole Sodium	61	23
Trazodone Hcl	Trazodone Hcl	60	22
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	60	25
Gabapentin	Gabapentin	57	26
Allopurinol	Allopurinol	56	21
Pradaxa	Dabigatran Etexilate Mesylate	56	20
Bisoprolol Fumarate	Bisoprolol Fumarate	55	25
Clopidogrel	Clopidogrel Bisulfate	44	18
Humulin N Kwikpen	Insulin Nph Human Isophane	43	18
Triamcinolone Acetonide	Triamcinolone Acetonide	43	33
Tamsulosin Hcl	Tamsulosin Hcl	42	20
Duloxetine Hcl	Duloxetine Hcl	39	21
Ibuprofen	Ibuprofen	35	24
Humulin N	Insulin Nph Human Isophane	33	14
Eliquis	Apixaban	31	suppressed
Terazosin Hcl	Terazosin Hcl	31	15
Lidocaine	Lidocaine	29	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	28	28
Finasteride	Finasteride	28	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	14
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	25	17
Ozempic	Semaglutide	25	12
Clonidine Hcl	Clonidine Hcl	24	suppressed
Ezetimibe	Ezetimibe	24	12
Alendronate Sodium	Alendronate Sodium	23	13
Fluticasone Propionate	Fluticasone Propionate	23	suppressed
Spiriva Respimat	Tiotropium Bromide	23	suppressed
Alvesco	Ciclesonide	22	11
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	22	11
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Cefadroxil	Cefadroxil	19	17
Liraglutide	Liraglutide	19	suppressed
Famotidine	Famotidine	18	11
Humulin R	Insulin Regular, Human	17	suppressed
Sertraline Hcl	Sertraline Hcl	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	11
Lactulose	Lactulose	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Victoza 2-Pak	Liraglutide	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Prednisone	Prednisone	14	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Temazepam	Temazepam	13	suppressed
Carvedilol	Carvedilol	12	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Nystatin	Nystatin	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Naproxen	Naproxen	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error